European regulator endorses high-dose version of Bayer eye drug Eylea

Bayer (BAYGn.DE) said on Friday that the European Medicines Agency recommended approval of a higher dose version of eye drug Eylea for treatment of a leading cause of blindness among the elderly, stepping up competition with Roche (ROG.S).